Logo of iaiPermissionsJournals.ASM.orgJournalIAI ArticleJournal InfoAuthorsReviewers
Infect Immun. 2002 Jul; 70(7): 3479–3492.
PMCID: PMC128085

Plasmodium vivax Promiscuous T-Helper Epitopes Defined and Evaluated as Linear Peptide Chimera Immunogens


Clinical trials of malaria vaccines have confirmed that parasite-derived T-cell epitopes are required to elicit consistent and long-lasting immune responses. We report here the identification and functional characterization of six T-cell epitopes that are present in the merozoite surface protein-1 of Plasmodium vivax (PvMSP-1) and bind promiscuously to four different HLA-DRB1∗ alleles. Each of these peptides induced lymphoproliferative responses in cells from individuals with previous P. vivax infections. Furthermore, linear-peptide chimeras containing the promiscuous PvMSP-1 T-cell epitopes, synthesized in tandem with the Plasmodium falciparum immunodominant circumsporozoite protein (CSP) B-cell epitope, induced high specific antibody titers, cytokine production, long-lasting immune responses, and immunoglobulin G isotype class switching in BALB/c mice. A linear-peptide chimera containing an allele-restricted P. falciparum T-cell epitope with the CSP B-cell epitope was not effective. Two out of the six promiscuous T-cell epitopes exhibiting the highest anti-peptide response also contain B-cell epitopes. Antisera generated against these B-cell epitopes recognize P. vivax merozoites in immunofluorescence assays. Importantly, the anti-peptide antibodies generated to the CSP B-cell epitope inhibited the invasion of P. falciparum sporozoites into human hepatocytes. These data and the simplicity of design of the chimeric constructs highlight the potential of multimeric, multistage, and multispecies linear-peptide chimeras containing parasite promiscuous T-cell epitopes for malaria vaccine development.

Malaria remains the most prevalent and devastating parasitic disease worldwide (3). While Plasmodium falciparum and Plasmodium vivax cause the majority of the approximately 300 million cases of malaria each year, the importance of P. vivax as a major public health challenge tends to be minimized by the extensive mortality due to P. falciparum in sub-Saharan Africa. P. vivax does, however, cause an estimated 80 million cases of malaria annually in South and Central America, India, Southeast Asia, and Oceania. Furthermore, rising drug resistance in this species now complicates the epidemiological spectrum of the disease (51). The search for new and improved tools, including the development of species-specific vaccines, to control infections caused by these Plasmodium species is imperative.

Separate malaria vaccines must be produced to target both P. falciparum and P. vivax, as the two species are quite distinct phylogenetically and antigenically (13). Malaria vaccines must also be able to target the exoerythocytic and blood stage forms of the parasite, generate both humoral and cellular immune responses, overcome genetic restriction, and stimulate memory cells.

Individuals living in areas where malaria is endemic develop an effective immunity capable of controlling parasitemia only after numerous infections, and repeated exposure is required to maintain this immunity (23). Experiments performed almost 40 years ago showed that complete protection could be provided by immunization with radiation-attenuated sporozoites (52). The focus since has been to determine which molecules or combination of molecules would be able to stimulate a similar protective immune response. Studies with rodent and nonhuman primate malaria models have shown that cellular as well as humoral immunity mechanisms have an important role in establishing a protective immune response (24). One widely studied target of this immunity is the circumsporozoite (CS) protein (54), which covers the surfaces of sporozoites, the liver-infective stage of the parasite. Proteins expressed by blood stage forms of the parasite can also confer protective immunity. One of the most extensively tested vaccine candidates from this stage is the merozoite surface protein-1 (MSP-1) (33). Investigations of the effector mechanisms involved in protection induced by immunization with MSP-1 suggest the involvement primarily of antibodies (7).

For these and other malaria vaccine candidate antigens, recombinant protein, DNA, and peptide immunogen approaches have been evaluated (32, 66). While there has been progress in generating immune responses with each approach, most immunogens tested have been limited in the ability to induce significant responses in a large number of genetically diverse individuals. Peptide immunogens offer several advantages (64), including the possibility of designing chimeras containing selected universal T-cell epitopes that can induce such responses. Qualitative and quantitative approaches have been used to identify universal T-cell epitopes. Allele-specific motifs were first demonstrated by isolating and subsequently sequencing class I self-peptides (15). The introduction of M13 phage display permitted the simultaneous characterization of several peptide-binding motifs (27). The introduction of methodology to isolate HLA class II molecules from Epstein-Barr virus (EBV)-transformed human B-cell lines, allowed peptide-binding interactions to be assayed by peptide competition experiments using biotinylated or radiolabeled indicator peptides (29). Using this approach, several universal epitopes have been defined for different pathogens, allergens, and autoantigens (38).

A malarial universal T-helper (Th) cell epitope described in the P. falciparum CS protein (45, 46) was recently shown to induce a significant antibody response in 7 of 10 individuals as part of a synthetic polyoxime-multiple-antigen peptide (MAP) immunogen (50). The prediction of this universal Th cell epitope through in vitro peptide-binding assays was validated in mice (5). These studies demonstrate that the abilities of synthetic peptides to interact with major histocompatibility complex (MHC) class II molecules can be directly correlated with their immunogenicity in vivo and that universal epitopes can induce a broad immune response that overcomes MHC restriction. Several HLA-DR promiscuous epitopes were subsequently described in P. falciparum preerythrocytic-stage proteins, but their in vivo relevance with regard to the development of immunity has not been reported (12).

Promiscuous T-cell epitopes have the inherent potential for functioning as universal epitopes (28). Based on the structural features of several DR alleles, pocket 4 interactions are known to determine the physical characteristics of amino acid residues in the amino-terminal portion of the binding peptides (4, 37). Peptides able to be adjusted at pocket 4 contain position 1 (P1) anchor residues, which are aromatic or hydrophobic residues (F, W, Y, L, I, V, or M). Secondary anchor residues have also been attributed to the sixth position (P6) in the linear peptide sequence and correspond to short or hydrophobic residues (S, T, C, A, P, V, I, L, or M). This structural pattern has been described as the P1-P6 motif and is a characteristic of a major group of DR alleles (65) that allows the promiscuous and potentially universal binding of epitopes.

In an effort to identify novel universal Plasmodium Th epitopes and to test their immunogenic functionality to overcome genetic restriction, we chose the P. vivax MSP-1 (PvMSP-1) molecule as our model. In comparison to P. falciparum MSP-1, the T-cell reactivity to PvMSP-1 has not been extensively characterized (10, 56). We constructed 86 PvMSP-1 peptides spanning this 210-kDa protein and used peptide competition assays to evaluate their binding to purified human class II alleles. The potential for their binding promiscuity was also analyzed based on their P1-P6 sequence motif patterns. The Th functions of eight selected peptide sequences were then studied by lymphoproliferation tests using cells from individuals with previous contact with P. vivax malaria and by analyzing the antibody and cytokine responses induced in mice immunized with Cys-T-B-Cys linear-peptide chimeras (LPCs) that include in tandem potential PvMSP-1 universal T-cell epitopes and the well-characterized immunodominant P. falciparum CS protein B-cell epitope, (NANP)3. This B-cell epitope is known to induce a significant antibody response in H-2b mice, while H-2d (BALB/c) mice have been considered nonresponders. Our data indicate that this genetic restriction to the (NANP)3 B-cell epitope can be overcome in H-2d (BALB/c) mice by including in the chimeric immunogens the PvMSP-1 promiscuous Th epitopes we identified. The Cys-T-B-Cys LPCs were exceptionally immunogenic in BALB/c mice and were able to elicit significant levels of neutralizing antibodies to the (NANP)3 B-cell epitope regardless of their H-2d genetic background. The potential and practicality of utilizing such LPCs for vaccine development is discussed.



After informed consent, blood samples (14 to 20 ml) from 63 individuals were collected aseptically in heparinized tubes. Thirty-three volunteers were adults from the area of Granada, in the Department of Meta in the eastern plains of Colombia (1), who had recently (within 30 days) recovered from an acute P. vivax malaria infection. Ten of these volunteers had antecedents of contact with both P. vivax and P. falciparum malaria. At the time of collection in 1999, P. vivax accounted for 64% of the total malaria cases in the area (26). A control group involved 30 healthy adults who were residents of Bogotá, Colombia (2,660 m above sea level), and had never lived in areas where malaria is endemic nor experienced any malaria infections. Peripheral blood mononuclear cells (PBMCs) were isolated on Lymphoprep (GIBCO Invitrogen Corp., Carlsbad, Calif.) within 24 h of blood collection. The cells were used in functional assays, and additional aliquots were cryopreserved as a source of antigen-presenting cells.

Mice and immunizations.

BALB/c (H-2d) mice were obtained from Charles River (Wilmington, Mass.). Groups of four female mice were immunized with 50 μg of the individual peptides tested emulsified in Freund's adjuvant (FA) (GIBCO Invitrogen Corp.); complete FA was used for the first immunization, followed by incomplete FA for subsequent immunizations. The mice received three intraperitoneal inoculations at 30-day intervals and were bled via the tail vein for antibody analyses 30 days after each immunization and at various time points following the final inoculation to reach a total of 300 days. The sera of each group were pooled for all antibody analyses. Two mice from each group were euthanized at day 200 to recover spleen cells for use in enzyme-linked immunospot (ELISPOT) assays. All animal protocols were approved by Emory University's Institutional Animal Care and Use Committee and followed accordingly.

HLA-DR heterodimer purification.

The following EBV-transformed homozygous B-cell lines were used as sources of human soluble class II molecules: DR1, WT100BIS [International Histocompatibility Workshop number 9006 (DRB1*0101)]; DR3, COX [WSNO 9022 (DRB1*0301)]; DR4, BSM [WSNO 9032 (DRB1*0401)]; and DR11, BM21 [WSNO 9043 (DRB1*1101)]. The B-cell lines were maintained in culture using RPMI 1640 medium supplemented with 2 mM l-glutamine, 50 μM 2-mercaptoethanol, 50 μg of streptomycin/ml, 50 U of of penicillin/ml, and 10% heat-inactivated fetal calf serum (FCS). Membrane proteins were extracted from 109 EBV- transformed B cells using 1% (vol/vol) Nonidet P-40 and a mixture of protease inhibitors, and the DRB1∗ heterodimers were purified by immunoaffinity procedures as described previously (29).

Synthetic peptides. (i) PvMSP-1.

Eighty-six 20-mer peptides spanning the complete PvMSP-1 protein from the Belem strain of P. vivax (GenBank accession number M60807 [9]) were synthesized by the multiple-solid-phase technique (Fig. (Fig.1).1). A series of amino- and carboxyl-terminally truncated peptides were also produced based on the sequences of peptides 19 and 53 (Table (Table1).1). All peptides were assembled using standard tert-butoxycarbonyl solid-phase peptide synthesis strategy on a p-methylbenzhydrylamine resin (Bachem California, Torrance, Calif.) as previously described (34). Briefly, tert-butoxycarbonyl N-protected amino acids were employed for peptide synthesis (Bachem California) and deblocked by trifluoroacetic acid treatment. Didyclohexilcarbodiimide was employed as the carboxy-activating reagent. Residues with low coupling efficacy required hydroxybenzotriazole activation (Aldrich Chemical, Milwaukee, Wis.). The optimum coupling reaction time was set to 1 h and monitored by the qualitative Kaiser test (61). The coupling step was repeated when necessary. Final peptide deprotection and cleavage was carried out by low-high hydrogen fluoride treatment and then the peptides were extracted using 5% acetic acid. Peptide purity was assessed by reverse-phase high-performance liquid chromatography, and the relative mass was characterized by spectroscopy.

FIG. 1.
Relative HLA class II binding profile of synthetic peptides spanning the complete sequence of PvMSP-1. Purified DRB1*0401, DRB1*0301, DRB1*1101, and DRB1*0101 and biotinylated control peptides were used in binding competition ...
Fine mapping of the antibody responses elicited against T-cell epitopes PvT19 and PvT53 by immunization with PvT19-PfB3 and PvT53-PfB3 peptide chimeras

(ii) Biotinylated indicator peptides.

The biotinylated peptides Gly-Phe-Lys-(Ala)7 [GFK(A)7] and GYR(A)6L for HLA-DR binding and competition experiments were synthesized using the biotin derivative sulfo-NHS-LC-biotin (Pierce Chemical, Rockford, Ill.). This derivative incorporates a six-carbon spacer long chain to increase the distance between the biotin moiety and the peptide. Biotin was coupled following the standard solid-phase peptide synthesis coupling procedure, and the efficacy was evaluated by the Kaiser test and standard enzyme-linked immunosorbent assays (ELISAs).

(iii) LPCs.

Six promiscuous peptide sequences selected for binding to purified DRB1∗ molecules were chosen to design 34-mer Cys-T-B-Cys LPCs. Based on our evaluation of published results concerning the immunogenicity induced with linear peptides containing T- and B-cell epitopes, a polarity of T-B was chosen (16-18, 55). The synthetic peptides thus contain the 20-mer T-cell epitope at the N terminus of the construct, immediately followed by the minimal P. falciparum NANP repeat, (NANP)3. Cysteine residues were added to the amino- and carboxyl-terminal ends of the peptides to allow polymerization of the peptides by oxidation (43). As controls, two peptides containing three (PfB3) or six (PfB6) NANP repeats were also synthesized with terminal cysteine residues (see Fig. Fig.3).3). In addition, a peptide containing the genetically restricted P. falciparum T1 epitope from the CS protein was produced (PfT1-PfB3) (47, 48).

FIG. 3.
Schematic representation of the Cys-T-B-Cys topology used to synthesize LPCs. The hatched bar represents the N-terminal position of the T-cell epitopes. The sequences for individual P. vivax epitopes described here (PvT4, PvT6, PvT8, PvT19, PvT45, and ...

Peptide-binding assays. (i) Peptide-binding ELISAs.

Peptide interactions with soluble HLA-DR molecules were measured using a peptide-binding ELISA (30). Class II molecules in the extracts were purified by immunoaffinity on a protein A-Sepharose anti-class II monoclonal antibody (MAb) column constructed using the MAb L-243 specific for DR (ATCC HB-55; American Type Culture Collection, Manassas, Va.). An optimal concentration of purified DR molecules was added to 96-well plates along with biotinylated indicator peptides (0.1 to 5 μM) in citrate-phosphate binding buffer containing 2% Nonidet P-40 and a mixture of protease inhibitors. Following incubation overnight, the peptide-class II complexes were transferred to wells coated with anti-HLA-DR MAb (L-243; 10 μg/ml). After a 2-h incubation at room temperature, the wells were washed with phosphate-buffered saline (PBS)/0.05% Tween 20, and the bound biotinylated peptide-class II molecule complexes were revealed by addition of alkaline phosphatase-labeled streptavidin (Vector Laboratories, Burlingame, Calif.) and substrate, 4-nitrophenylphosphate (KPL, Gaithersburg, Md.). Optical densities (ODs) were determined in a Multiskan ELISA reader (Labsystems, Franklin, Mass.) using a 405-nm filter.

(ii) Peptide-binding competition assays.

Peptide-binding competition assays were conducted to measure the abilities of unlabeled peptides to compete with biotinylated indicator peptides for binding to purified HLA-DR molecules. For these assays, biotinylated polyalanine 9- or 10-mer peptides containing allele-specific binding motifs were used (5). For DRB1∗0101, DRB1∗0401, and DRB1∗1101 assays, biotinylated GFK(A)7 was used as the indicator peptide. Similarly, the appropriate biotinylated GYR(A)6L peptide was used as the indicator peptide for DRB1∗0301. These indicator peptides were implemented previously to define HLA-binding peptides, and their affinity for HLA molecules is well characterized (5). According to this assay, a good competitor is a peptide capable of inhibiting over 50% of the binding of the indicator peptide to the HLA molecule being tested.

The biotinylated indicator peptide and class II molecules were incubated with 5- to 10-fold dilutions (0.001 to 100 μM) of the unlabeled PvMSP-1 competitor peptides. Binding was determined by measuring the OD in the presence versus the absence of competitor peptide. Inhibition was calculated as a percentage using the following formula: 100 × [1 − (ΔOD with competitor peptide/ΔOD without competitor)].

Antibody assays. (i) Standard ELISAs.

The fine specificity of the antibodies elicited by immunization with individual chimeras was determined by ELISA using Immulon-2 plates (Dynatech Laboratories, Chantilly, Va.) coated with 1 μg of peptides/ml representing the T-cell epitopes, the polymeric B-cell epitope, or the Cys-T-B-Cys LPCs. The abilities of the peptides to bind the ELISA plates were determined by in situ biotinylation as described previously (25). After being blocked, the plates were incubated with sera diluted in PBS with 2.5% bovine serum albumin for 1 h at 37°C, and the bound antibodies were then detected using peroxidase-labeled goat anti-mouse immunoglobulin G (IgG) and H2O2-2,2′-azinobis (3-ethylbenzthiazoline-6-sulfonic acid) (KPL) as a substrate. ODs were determined using a VERSAmax ELISA reader (Molecular Device Corp., Sunnyvale, Calif.) with a 405-nm filter. The endpoint was measured as the highest dilution of sera having a ΔOD greater than the mean plus two standard deviations obtained using nonimmune sera. Individual serum, analyzed at different time points, showed no significant differences among the groups. Final titers were then determined using pools of sera.

(ii) Subtype determinations.

Isotype profiles of the antibodies elicited by immunization with the LPCs were also determined by ELISA. After serum incubation, the plates were washed and incubated with biotinylated rat anti-mouse MAbs IgG1, IgG2a, IgG2b, IgG3, IgE, or IgM (BD PharMingen, Franklin Lakes, N.J.) or biotin-labeled goat anti-mouse IgA (KPL) for 90 min. After the plates were washed, the bound antibodies were detected using horseradish peroxidase-streptavidin (BD PharMingen) and H2O2-2,2′-azinobis (3-ethylbenzthiazoline-6-sulfonic acid) as a substrate.

The affinities of anti-peptide antibodies were assessed by a thiocyanate elution-based ELISA (44). The procedure was similar to that described above for the standard ELISAs with the inclusion of an extra step. After the plates were washed following incubation of the pooled serum dilutions, ammonium thiocyanate in PBS was added to the wells in duplicate in concentrations ranging from 0 to 8 M. The plates were allowed to stand for 15 min at room temperature before they were washed and the assay proceeded as described above. The concentration of ammonium thiocyanate required to dissociate 50% of the bound antibody was determined by linear regression analysis.

(iii) ISI assays.

Inhibition of sporozoite invasion (ISI) assays were performed as described previously (42). Briefly, human hepatoma cell line HepG2 A16 cells were collected after trypsinization and plated at 50,000 per well in glass Lab-Tek chamber slides (Nunc, Rochester, N.Y.). Pools of sera were added in triplicate in a volume of 50 μl at 1:50 dilution. P. falciparum sporozoites (NF54 strain) were obtained from infected Aedes stephensi mosquitoes and adjusted to 2 × 104/50 μl of medium. The sporozoites were added to the hepatoma cells to a final serum dilution of 1:100 and incubated for 3 h at 37°C. The culture was subsequently washed and fixed with cold methanol. The parasites were visualized by immunocytochemistry using the P. falciparum-specific MAb NFS1 (42). This MAb was also used as a positive control of inhibition, and cultures with normal sera served as negative controls. The average numbers of exoerythrocytic stage forms (EEF) in triplicate cultures were recorded, and percent inhibition was calculated with the following formula: [1 − (mean number of EEF in cultures with immune serum/mean number of EEF in cultures with normal serum)] × 100.

(iv) Indirect IFAs.

Sera obtained from mice immunized with the same synthetic peptide constructs were pooled, and the antibody reactivity was evaluated by indirect immunofluorescence assays (IFAs) using air-dried P. falciparum (NF54 strain) sporozoites and acetone-fixed P. vivax schizonts, kindly provided by John W. Barnwell. Several serum dilutions were tested, and the reactivity was evaluated using fluorescein isothiocyanate-labeled goat anti-mouse IgG (KPL) diluted in PBS-0.4% Evans Blue.

T-cell lines and lymphoproliferation assays.

Terminal T-cell lines were established from the volunteer participants' PBMCs immediately after isolation by cultivation in RPMI 1640 medium supplemented with 2 mM l-glutamine, 1% nonessential amino acids (GIBCO Invitrogen Corp.), 1 mM sodium pyruvate, 25 U of penicillin/ml, 50 μg of streptomycin/ml, and 5 × 10−5 M 2-mercaptoethanol (complete RPMI), with 10% heat-inactivated AB+ serum (ICN Biomedicals, Costa Mesa, Calif.). The cells were incubated with a peptide pool containing a total 10-μg/ml final concentration of individual 20-mer synthetic peptides representing eight different regions of the PvMSP-1 protein selected by their abilities to bind four different MHC alleles. After 3, 7, and 10 days of culture at 37°C in 5% CO2, the cells were supplemented with complete RPMI-10% FCS containing 100 U of recombinant interleukin-2 (IL-2) (BD PharMingen)/ml.

Lymphoproliferation assays were performed using 2 × 104 T cells from the T-cell lines described above and 5 × 104 autologous PBMCs inactivated with mytomicin C (Sigma, St. Louis, Mo.) as antigen-presenting cells. The cells were incubated with complete RPMI supplemented with 10% FCS in 96-well plates in the presence or absence of individual peptides at 1 and 10 μg/ml. Phytohemagglutinin P and staphylococcal enterotoxin B were included as positive controls of proliferation. After 48 h, the cultures were pulsed overnight with 1 μCi of [3H]thymidine (Amersham-Pharmacia, Little Chalfont, Buckinghamshire, United Kingdom)/well and harvested on glass filters, and the specific incorporation was evaluated by liquid scintillation counting. The results are expressed as the stimulation index (SI), calculated as the mean counts per minute in triplicate peptide-stimulated wells/mean counts per minute in medium-treated control wells. T-cell responses are considered positive for cases in which the SI is higher than 2.

ELISPOT assays.

The frequency of murine peptide-specific T lymphocytes was determined in two mice with gamma interferon (IFN-γ)- and IL-5-specific ELISPOT assays conducted 200 days after the first immunization, when the antibody responses reached a plateau. The assays were performed in nitrocellulose microplates (Millipore, Bedford, Mass.) coated with rat capture anti-mouse IFN-γ or rat anti-mouse IL-5 (PharMingen) (10 μg/ml) in PBS. Duplicate aliquots of different concentrations (1 × 106 and 5 × 105) of freshly isolated spleen cells from immunized mice were plated in RPMI containing 10% FCS. Th cells were activated by the addition of 10 μg of LPCs/ml or peptides representing B- or T-cell epitopes alone. After 24 h for IFN-γ and 48 h for IL-5, the plates were washed and incubated with 2 μg of biotinylated rat anti-mouse IFN-γ/ml and 5 μg of biotinylated rat anti-mouse IL-5 (PharMingen)/ml and followed by incubation with streptavidin-horseradish peroxidase. The reaction was developed using 3,3-diaminobezidine-tetra-hydrochloridedehydrate (Sigma) and evaluated in an Immunospot analyzer (Cellular Technology-Becton Dickinson, San Diego, Calif.).

Statistical analysis.

Stimulation indexes were analyzed using the Mann-Whitney U test. Linear correlation was calculated to evaluate the relationship among ISI and IFA titers, antibody isotype profiles, and affinity assays. For affinity of anti-peptide antibody assays, the concentration of ammonium thiocyanate required to dissociate 50% of bound antibodies was determined by linear regression. The significance of differences in cytokine production between cells stimulated in vitro with and without synthetic peptides was analyzed with Student's t test following log10 transformation to normalize the distribution of data; P values of 0.05 or less were considered to be significant.


Identification of peptides promiscuous for binding to purified DRB1∗ in PvMSP-1 by utilizing peptide-binding assays.

To identify P. vivax Th cell epitopes, 86 PvMSP-1 peptides were synthesized and tested for the ability to bind to four purified DRB1* molecules (Fig. (Fig.1).1). These peptides are not overlapping but cover the entire 1,726-amino-acid sequence of PvMSP-1 (Fig. (Fig.2A).2A). They therefore represent a good starting point for assessing the presence of Th cell epitopes in this protein, but not necessarily all possible Th cell epitopes. Binding to DRB1* molecules was indirectly assayed in vitro in a competitive binding assay utilizing GFK(A)7 and GYR(A)6L competing biotinylated indicator peptides, for which binding to these molecules has been well characterized.

FIG. 2.
(A) Schematic representation of PvMSP-1 and localization of the promiscuous T-cell epitopes described here. The amino acid sequence identity between the Belem and SalI sequences are adapted from the report by Gibson et al. (22). Peptide amino acid sequences ...

Since we were aiming to identify promiscuous peptides capable of binding a broad range of HLA molecules, the peptides were assayed for binding to DRB1*0301, DRB1*0401, and DRB1*1101, as well as DRB1*0101. Eight peptides (no. 4, 6, 8, 19, 25, 45, 47, and 53) bound all four DR molecules. Six of these peptides (no. 4, 6, 8, 19, 45, and 53) are topologically distributed in relatively conserved segments of the PvMSP-1 protein (Fig. (Fig.2A).2A). Peptides 19 and 53, representing amino acids (aa) 378 to 397 (LEYYLREKAKMAGTLIIPES) and 1058 to 1077 (SKDQIKKLTSLKNKLERRQN), are 100% identical in the two completed PvMSP-1 sequences (Belem and Salvador I strains) reported (9, 22). Additionally, peptides 4 (aa 78 to 97; NFVGKFLELQIPGHTDLLHL), 6 (aa 118 to 137; FNQLMHVINFHYDLLRANVH), and 8 (aa 158 to 177; LDMLKKVVLGLWKPLDNIKD), which are clustered near the N terminus, exhibit 90% identity, with only two amino acid differences (boldface). Peptide 45 (aa 898 to 917; KKIKAFLETSNNKAAAPAQS), on the other hand, has three amino acid differences with 85% identity. In contrast, a set of partial available sequences of PvMSP-1 containing the peptide 25 sequence (aa 498 to 517) confirms polymorphisms at four amino acid positions (AKVNEFKPAFNHFYEARLDN) (6), and peptide 47 (aa 938 to 957) is located in a region of PvMSP-1 that exhibits very low amino acid identity (22). We also found that 58, 54.4, and 46.5% of the 86 PvMSP-1 peptides were able to bind specifically to DRB1*0301, DRB1*0401, and DRB1*1101, respectively. Moreover, several peptides bound to two or three types of these DR molecules; 26.7% bound two of the DR alleles, and 24.4% bound to all three.

Recognition of the PvMSP-1 class II promiscuous-binding peptides by human T cells.

To determine whether the eight promiscuous PvMSP-1 peptides that bound all four DR molecules in the peptide-binding assays are recognized by T cells of individuals with a history of P. vivax malaria infections, T-cell proliferation responses to these peptides were assessed from samples acquired from 33 volunteers living in a region of Colombia, South America, where P. vivax is endemic. Each individual had previously documented P. vivax infections and, in some cases, P. falciparum malaria. Control samples were also obtained from nonexposed volunteers living in areas where P. vivax is not endemic. Terminal T-cell lines were tested for proliferation, after 10 days of specific PvMSP-1 peptide stimulation, with autologous mitomycin-treated PBMCs as antigen-presenting cells. Although the DRB1* allele prevalence could not be determined in this cohort of individuals, the alleles tested for binding represent over 70% of the Hispanic populations, assuming a representative main subtype (12, 65).

Consistent with the broad pattern of HLA-DR binding we observed, most of the DRB1*-selected synthetic peptides elicited a proliferative response in the cells from volunteers with previous contact with P. vivax malaria but not in the cells from nonexposed individuals (Fig. 2B and C). The frequency of responders among exposed individuals ranged from 18 to 48%, in contrast to 3 to 23% for nonexposed volunteers. Differences between groups were statistically significant for peptides 4, 6, 8, 19, 25, and 45 (P < 0.05). Most of the responders showed reactivity to more than one peptide; however, none of the volunteers responded to all of the peptides. All of the donor cells showed positive responses to both phytohemagglutinin-P and staphylococcal enterotoxin B, with SIs ranging from 2.8 to 164.

Design of LPCs to study the Th activity of the six most conserved PvMSP-1 potential universal Th epitopes.

The six promiscuous PvMSP-1 peptides displaying the highest conservation, as noted above, were selected for development of Cys-T-B-Cys LPC chimeras and were renamed PvT4, PvT6, PvT8, PvT19, PvT45, and PvT53, corresponding to their original peptide numbers (Fig. (Fig.3).3). Interestingly, five of these six linear peptides contain at least one or several overlapping P1-P6 DR allele structural binding motifs (65), which are noted in boldface as follows: PvT4, NFVGKFLELQIPGHTDLLHL; PvT6, FNQLMHVINFHYDLLRANVH; PvT8, LDMLKKVVLGLWKPLDNIKD; PvT19, LEYYLREKAKMAGTLIIPES; and PvT53, SKDQIKKLTSLKNKLERRQN. The B-cell epitope selected for inclusion in the LPCs is the repeat tetramer (NANP)n of the P. falciparum CS protein. Antibody responses to this epitope have been extensively characterized in several models (42, 47, 57), and they are known to be able to neutralize sporozoites and inhibit their invasion of hepatocytes (42). An additional chimeric peptide, which includes a genetically restricted Th epitope of the CS protein (PfT1) that is unable to provide help for antibody production against the (NANP)n sequence in H-2d mice, was used as a control (47).

The accessibility of the PfCS (NANP)3 repeat B-cell epitope in these constructs was determined by ELISA using the specific PfCS protein MAb 2A10. Figure Figure4A4A shows the profiles of recognition of the different Cys-T-B-Cys LPCs. Most of the peptides were recognized by MAb 2A10 at concentrations as low as 0.048 ng/ml. Nonetheless, the PvT4-PfB3, PvT6-PfB3, and PvT8-PfB3 constructs were not recognized as efficiently as the others, suggesting the presence of structural constraints associated with polymerization which could prevent or limit exposure of the B-cell epitope. The results also demonstrate better reactivity with the PfB6 construct than with the PfB3 peptide. Based on these observations, the peptide containing six repeats (PfB6) rather than three was selected for the subsequent fine characterization of the anti-NANP antibodies elicited by immunization with the Cys-T-B-Cys LPCs.

FIG. 4.
(A) Antigenicities of the LPCs determined with anti-CSP MAbs. ELISA plates were coated with 1 μg of the individual LPCs/ml and assayed with several dilutions of P. falciparum (2A10) anti-repeat MAbs. The data are presented as ODs obtained at different ...

Differences in recognition by the MAb could also be attributed to dissimilar adsorption of peptides to the ELISA plate. To test this, various concentrations of peptide ranging between 0.19 and 100 ng/ml were used to coat ELISA plates, and in situ biotinylation assays were conducted to measure the amounts of peptide bound to the plates (25). The PvT19-PfB3, PvT45-PfB3, and PvT53-PfB3 chimeras were detected at concentrations as low as 0.19 ng/ml. In contrast, PvT4-PfB3, PvT6-PfB3, and PvT8-PfB3 were detected in the range of 10 to 100 ng/ml. Dissimilarities in the efficacies of biotinylation could explain such differences. In fact, PvT4-PfB3 and PvT6-PfB3 contain only two reactive groups in comparison to the four to eight groups contained in the PvT8-PfB3, PvT19-PfB3, PvT45-PfB3, and PvT53-PfB3 chimeras.

Immunogenicity of LPC constructs in mice.

The immunogenicity of the peptide chimeras were tested in BALB/c mice. It is well known that these mice do not produce significant levels of antibodies upon (NANP)n immunization, regardless of whether the repeats are included in recombinant protein or peptide constructs (47, 57). Groups of four mice were immunized three times intraperitoneally with 50 μg of individual Cys-T-B-Cys chimeras or the control peptides PfB3 and PfB6 emulsified in complete or incomplete FA, and the antibody responses were followed for 300 days by ELISA using PfB6 as an antigen (Fig. (Fig.4B).4B). In mice immunized with PfB3, or an allele-specific T-cell epitope (PfT1), the antibody responses to the PfB6 (NANP) sequence were very low and boosting did not change the pattern of the responses. In fact, these antibody titers mimic those obtained upon immunization with saline (Fig. (Fig.4B).4B). However, the PfB6 construct induced significant levels of antibodies, which were boosted by each immunization. The inclusion of P. vivax promiscuous T-cell epitopes in the LPCs dramatically increased the responses to the (NANP)3 sequence, with titers reaching a peak at day 120 and antibody titers ranging between 1:2 × 105 and 1:3.3 × 106. Single immunizations with PvT4-PfB3, PvT6-PfB3, PvT8-PfB3, and PvT19-PfB3 chimeras were able to induce antibody responses with titers over (1:2) × 104. Lower but substantial antibody titers were obtained after boosting with the chimeras PvT4-PfB3, PvT6-PfB3, PvT8-PfB3, and PvT45-PfB3, which all consistently had lower recognition by MAb 2A10. Strikingly, the antibody levels remained essentially the same for the 300-day period evaluated.

Antibodies induced by the immunogens were also evaluated by ELISA using individual chimeras as antigens. The magnitudes and kinetics of the antibody titers followed patterns of recognition similar to those obtained with PfB6 as the antigen (data not shown). The antibody responses peaked 60 days after the last immunizations, with titers ranging between (1:1) × 105 and (1:1.3) × 107. Importantly, the PvT19-PfB3 and PvT53-PfB3 immunogens induced an antibody peak followed by a plateau at day 90 with ELISA titers up to (1:1.3) × 107 against the corresponding LPCs. This contrasts with the final titers of (1:3.2) × 106 and (1:1.6) × 106 obtained with the PfB6 construct. These results suggest that PvT19-PfB3 and PvT53-PfB3 contain additional B-cell epitopes. To characterize the potential recognition of the T-cell epitope-containing peptides by antibodies elicited by the PvT19-PfB3 and PvT53-PfB3 immunogens, a new set of synthetic peptides containing amino- and carboxyl-terminal truncations were synthesized and tested by ELISA. Table Table11 summarizes the responses using pools of serum obtained at day 120. These results suggest that the T-cell epitope-containing peptide PvT53-PfB3 contains two different B-cell epitopes. In contrast, the minimal B-cell epitope recognized by immunization with the chimera PvT19-PfB3 seems to be present in a 16-mer core region. The presence of B-cell determinants in the Th sequences could explain the higher immunogenicities of both peptides in comparison with other chimeras.

Several reports have indicated that different antibody isotypes are involved in protection elicited by natural contact with malaria parasites. We therefore determined the IgG subtypes in the sera from the mice immunized with the individual Cys-T-B-Cys LPCs. High antibody responses mediated by IgG1, IgG2a, and IgG2b were obtained with all of the chimeras. However, mice immunized with PvT4-PfB3, PvT8-PfB3, and PvT19-PfB3 more consistently elicited anti-repeat antibodies of all IgG subclasses. In contrast, the antibody responses elicited with PvT6-PfB3, PvT45-PfB3, and PvT53-PfB3 were predominantly of the IgG1 and/or IgG2b subtype (Table (Table2).2). This suggests that different populations of Th cells are induced after immunization with chimeras containing the P. vivax promiscuous T-cell epitopes. Only constructs based on peptides PvT6 and PvT19 induced significant levels of IgG3.

Inhibition of P. falciparum sporozoite invasion (ISI) of HepG2.16 hepatoma cells by sera obtained from mice immunized with peptide chimeras and comparison with anti-sporozoite antibody titers, anti-peptide antibody isotype profiles, and affinities of ...

Cellular immune responses.

To characterize the prevalence of peptide-specific T lymphocytes, at day 200, two mice from individual groups were euthanized and their pooled spleen cells were assessed for the presence of IFN-γ- and IL-5-secreting cells (Table (Table3).3). The cultures were pulsed with peptides representing T-B-, T-, or B-cell epitopes. A negative control using only cells cultured in medium was included, and a combination of phorbol 12-myristate 13-acetate and ionomycin served as a positive control. Spleen cells from mice immunized with different LPCs showed T-cell epitope-specific IFN-γ production. There were no significant differences in IFN-γ secretion when the cells were tested with PfB6 or the corresponding LPCs. In contrast, we determined significant differences in IL-5 production after in vitro stimulation with PfB6, LPCs, or peptides representing the T-cell epitopes (Table (Table33).

Comparison of the number of spot-forming cells per 106 spleen cells determined by ELISPOT

Biological activity of anti-peptide antibodies.

To be effective, anti-peptide antibodies induced by immunization should be able to recognize the parasites' native proteins. For this reason serum samples were tested by IFA analyses with P. falciparum sporozoites and P. vivax schizonts (blood stage forms) to assess the reactivities of the antibodies with the surface of the sporozoite and merozoite stages of the parasite, respectively. These assays were conducted with sera obtained 60 days after the third immunization, when the anti-peptide reactivity reached a peak. Antibodies generated by the PvT19-PfB6 and PvT53-PfB6 chimeras recognize P. vivax merozoites at 1:1,600 dilutions (data not shown). In sharp contrast, none of the serum pools obtained from mice immunized with PvT4-PfB6, PvT6-PfB3, PvT8-PfB3, PvT45-PfB3, or control peptides were positive by this type of assay.

Antibodies recognizing the P. falciparum sporozoites were more complex and differed depending upon the construct used (Table (Table2).2). T-B chimeras containing the P. vivax Th epitopes produced a range of anti-sporozoite responses, with IFA antibody titers as low as 1:800 for the PvT8-PfB3 construct and as high as 1:409,600 for the PvT19-PfB3 construct. These constructs could be grouped as high responders (PvT6-PfB3, PvT19-PfB3, and PvT53PfB3), intermediate responder (PvT4-PfB3), and low responders (PvT8-PfB3 and PvT45-PfB3). Further, constructs PfB3 and PfB6 and the PfT1-PfB3 constructs induced much greater anti-sporozoite antibody titers than we had expected, suggesting that the polymerization of the peptides due to the presence of the terminal Cys residues had in fact increased the representation and immunogenicity of the B-cell epitopes in these constructs.

The biological relevance of these antibodies was also evaluated by testing their abilities to inhibit the invasion of target cells. As expected, the greatest inhibition was observed with the antisera that showed the highest reactivities to sporozoites. An interesting observation, however, is that construct PfB6, in spite of its lower anti-sporozoite titer, produced a higher inhibition than T-B chimeras with intermediate or low levels of anti-sporozoite responses. The ISI assays were correlated with anti-peptide antibody titers (total IgG, IgG isotypes, IgM, IgE, and IgA) (Table (Table2),2), IFA analyses, and antibody affinity assays. There were positive correlations between ISI and titers evaluated by IFA against P. falciparum sporozoites (r = 0.905; P = 0.0025), total IgG (r = 0.909; P = 0.0023), IgG1 (r = 0.836; P = 0.009), IgG2a (r = 0.752; P = 0.025), IgG2b (r = 0.782; P = 0.018), IgA (r = 0.811; P = 0.013), and the total IgG antibody affinity (r = 0.814; P = 0.012), but not with IgG1, IgE, or IgM.


Various strategies have been used to define and characterize antigens involved in protective immune responses against Plasmodium. The complexity of the malaria parasite life cycle, with many stage-specific antigens and a multitude of possible effector mechanisms and immune evasion strategies, remains a tremendous obstacle. The search for ideal immunogens has largely revolved around the identification of exposed surface antigens, conserved regions specifically involved in the invasion of host cells or sequestration processes, and the characterization of B-cell epitopes. Malaria vaccine clinical trials to date, based on a few selected antigens, have shown limited immunogenicity and failure to induce long-lasting immunity, suggesting the lack of effective Th cell epitopes in the constructs used as immunogens (40, 49). Nevertheless, there have been only a few Th cell epitopes reported from malaria antigens (58). A major impediment for identifying Th cell epitopes is the high level of polymorphism of HLA class II molecules. Accordingly, one of the most relevant steps for malaria vaccine development is to define Th cell epitopes that can interact promiscuously with a broad range of DR molecules. We have begun this process with the P. vivax reticulocyte binding protein-1 (PvRBP-1) (20) (unpublished data) and the P. vivax MSP-1 (9) vaccine candidate antigens.

Several factors contributed to our decision to initiate this study with PvMSP-1 as a primary model: (i) epidemiological evidence of broad PvMSP-1 recognition by lymphocytes from people living in areas of endemicity (63), (ii) evidence in clinical and preclinical trials with different Plasmodium species that partial protection could be induced in susceptible hosts by immunization with vaccine candidates based on MSP-1 (33), (iii) indications that proliferation and production of cytokines could be elicited in vivo and in vitro using recombinant MSP-1 constructs (10, 21), and (iv) our objective to increase the knowledge base on immunity to P. vivax antigens. Further, genetic diversity of MSP-1 has been suggested to contribute to the parasite's immune evasion strategies. T-cell epitopes described previously in polymorphic regions of MSP-1 from P. falciparum have been reported to exhibit genetic restriction, inducing responses in a limited number of individuals (56).

Our analysis of PvMSP-1 is the most comprehensive assessment to date of promiscuous Th cell epitopes contained in the Plasmodium MSP-1 malaria vaccine candidate antigen. In fact, to our knowledge, this is the most thorough analysis of the presence of Th cell epitopes for any Plasmodium antigen. Moreover, we show that the promiscuous epitopes defined for PvMSP-1 can provide significant T-cell help for the P. falciparum (NANP)3 B-cell epitope. This observation suggests that the data reported here have potentially much larger implications. If in fact certain T-cell epitopes defined for this or other Plasmodium antigens can provide significant T-cell help for various Plasmodium antigens, or even other types of antigens, their potential utility could be wide ranging. Previous experiments designed to evaluate the in vivo significance of the association of B- and T-cell epitopes in immunogens have shown that the magnitude of the response is limited by low T-cell epitope density (2). Peptide dendrimers, including MAP constructs, which consist of linear peptides attached to a core matrix, have been considered promising approaches to develop peptide vaccines with a high density of B- and T-cell epitopes (68). The combination of B- and T-cell epitopes in Plasmodium-specific traditional MAP structures led to a sustained protective immune response in murine models (68) and a strong antibody response, lymphoproliferation, and cytokine production in human volunteers (49, 50). Nevertheless, the production of these MAPs requires very precise stoichiometry yet results in heterogeneous final products and very poor yields (2, 36). The addition of cysteine residues to anchor peptides to the core matrix is a recent improvement that has facilitated the inclusion of several epitopes in MAPs, as well as the characterization of the in-process product (2, 39). However, the process of developing and analyzing MAP constructs remains complex and costly compared to linear peptides.

We sought a simpler and more economical approach for presenting a high density of Plasmodium epitopes, with the goal of designing constructs that were easy to produce, easy to characterize, stable, and highly immunogenic. Consequently, a high density of B- and T-cell epitopes was obtained using the straightforward approach of adding cysteine residues at the amino- and carboxyl-terminal ends of linear-peptide T-B chimeras (43, 59) (Fig. (Fig.3).3). The cysteine residues enabled the LPCs to spontaneously polymerize (43). The antigenicity of the constructs was confirmed by ELISA using a MAb specific to the (NANP)3 B-cell epitope, and recall T-cell responses were assessed by conducting lymphoproliferation assays. The immunogenicity of the polymers was evaluated in mice in the absence of carrier molecules, as we had also hoped to be able to bypass the need for carriers and ultimately strong adjuvants. The resulting LPC immunogens were highly effective, with the resulting humoral immune response far surpassing the antibody levels previously observed for the extensively studied (NANP)3 B-cell epitope (8, 39, 42, 47, 57). Furthermore, the ability of the LPCs to overcome genetic restriction to the (NANP)3 B-cell epitope in BALB/c mice and the observed potential for isotype class switching and cellular recall responses add strong support for further basic and preclinical evaluation of the LPC approach for malaria vaccine development.

The rationale behind developing chimeras containing a P. falciparum B-cell epitope, and not a P. vivax B-cell epitope(s), was based on the fact that the immune response against the P. falciparum NANP repeat is particularly well characterized (5, 47). We were also testing the hypothesis that P. vivax Th epitope sequences could provide help to an unrelated antigen. In spite of the fact that the phylogenetic distance of P. vivax and P. falciparum has led to them being largely antigenically distinct species, our data suggest that there may be ways to combine effective epitopes from multiple species to produce a multispecies malaria vaccine. Whereas the concept of multistage epitope vaccines was adopted about 20 years ago (53), with cocktail approaches being investigated since to develop multicomponent P. falciparum vaccines, the concept of a multispecies malaria vaccine has not yet been pursued. Our finding that the P. vivax Th epitopes can provide help to generate a significant antibody response against the P. falciparum (NANP)3 B-cell epitope is the first demonstration of a multispecies malaria vaccine immunogen.

Our results show that eight out of 86 20-mer PvMSP-1 peptides bind competitively to human DRB1∗ alleles, which have been shown to represent over 70% of individuals in Hispanic populations (12, 65). In contrast to the definitive class I binding of 8- to 10-mer peptides, class II molecules show promiscuity in their association with peptides 10 to 20 amino acids long (31). Six out of the eight promiscuously binding peptides induced a spectrum of lymphoproliferation reactivities in 24 to 48% of individuals with prior contact with P. vivax, consistent with a recall response. This is in sharp contrast with the reactivity in 3 to 23% of normal volunteers, results that have been previously reported in malaria, and is consistent with the broad promiscuity of MHC class II association or cross-reactivity (23, 62). This percentage of reactivity is very close to the frequency found in individuals exposed to P. vivax malaria in areas of Brazil with similarly low endemicity, where the prevalence of recall lymphoproliferative responses to PvMSP-1 N-terminal recombinant proteins was reported to be 30 to 47.2% (63). Nevertheless, the prevalence of recognition observed for the PvMSP-1 peptide sequences is lower than that reported in other systems (11). This could be attributed to the fact that the PvMSP-1 studies were conducted without CD4 enrichment and using PBMCs derived from volunteers living in an area of low malaria endemicity. Although all volunteers had previous P. vivax infections, a comparatively low prevalence of memory cells would be expected in an area of low endemicity versus an area of high endemicity (63). Hence, the positive recognition of the PvMSP-1 peptide sequences by recall lymphocytes that we observed is in fact striking. Typically, T-cell epitope recognition by nonfractionated cells is obtained only with the use of antigen-presenting cells, such as dendritic cells, with strong costimulatory activity and a high MHC-peptide complex density (41).

Importantly, we identified significant IFN-γ production after in vitro stimulation with peptides representing the promiscuous T-cell epitopes. IFN-γ has been involved as a key effector molecule in the clearance of malaria parasites (67). The PvT45 peptide (KKIKAFLETSNNKAAAPAQS) induced a particularly high level of IFN-γ-producing cells and deserves additional characterization. Interestingly, while DNA immunizations with plasmids containing Pvmsp-1 sequences are immunogenic in mice (10), with DNA representing the amino-terminal (682-aa) and 19-kDa carboxyl-terminal regions generating significant antibody responses, only the plasmid representing the amino-terminal portion consistently induced IFN-γ production (10). Four out of the six promiscuous peptide sequences we identified correspond to this region. In contrast, no IFN-γ production was observed in a recent study of the immunogenicity of a series of MAP constructs representing P. falciparum MSP-1, CS, and liver stage antigen-1 epitopes (39). This study also demonstrated strong genetic restriction of these MAP immunogens in several strains of mice, including BALB/c.

Another recent study using peptide-binding assays on filter papers with soluble DRB1∗0101 and DRB1∗0405 biotinylated molecules identified several P. falciparum MSP-1 T-cell epitopes, with a high percentage (8.3 to 25.8%) of promiscuity noted (19). However, this study did not entail a complete survey of peptides representing the entire protein and did not utilize competition peptide-binding assays. While the present binding analyses of 86 PvMSP-1 peptides, which resulted in the identification of eight unique promiscuous T-cell epitopes that bind DRB1*0301, DRB1*0401, DRB1*1101, and DRB1*0101 alleles, is certainly more thorough, it is important to realize that since these are not overlapping peptides, additional potential PvMSP-1 T-cell epitopes could have escaped detection. Thus, it remains uncertain how many are actually present across this protein. In any case, the dramatic Th cell response attributed to several of our PvMSP-1 Th epitopes brings to light the question of how many such epitopes will be satisfactory for the development of an effective malaria vaccine. If epitopes like the ones defined here can show a broad Th activity for CS protein antibody expression, it is reasonable to predict that they could have a similar potential for other B-cell epitopes as well. It is now critical to determine the fullest potential of these sequences. If they can provide essential Th activity to various B-cell epitopes, we must question the relevance of further extensive searching for novel promiscuous Th cell epitopes in various Plasmodium vaccine candidate antigens.

Analysis of the antibody response to the chimeras containing the PvMSP-1 peptide sequences Pv19 and Pv53, which elicited the highest antibody titers against the T-B peptides, suggests the presence of novel B-cell epitopes within the PvMSP-1 Th epitope sequences. The results are quite remarkable for the persistence of the immune response, with anti-peptide antibody titers between 1:2.5 × 104 and 1:1.6 × 106 detected up to 300 days after the first immunization. Importantly, antibodies elicited against these LPCs were also found to recognize P. vivax merozoites, showing a classic MSP immunofluorescence staining pattern for the surface of the merozoites (33). On the other hand, all constructs with the (NANP)3 sequence elicited antibodies that reacted by IFA with the surfaces of P. falciparum sporozoites and were able to inhibit invasion of target hepatocytes in a classical ISI assay.

When antibody isotypes relating to the individual LPCs were assessed, distinct patterns were observed. Similar titers of IgG1, IG2a, and IgG2b were induced in mice immunized with the chimeras PvT4-PfB3, PvT8-PfB3, and PvT19-PfB3, suggesting that the Th activity includes both Th1- and Th2-type responses. In contrast, the predominant IgG subtypes in mice immunized with chimeras PvT6-PfB3, PvT45-PfB3, and PvT53-PfB3 were IgG1 and IgG2b, suggesting a predominant Th2 activity. The production of anti-peptide IgA and a low level of IgE antibodies is also noteworthy; so far, though, the IgE titers have been very low and would not seem to pose safety concerns. Consistent with the Th2 and IgA antibody profiles, a significant number of IL-5-secreting cells were detected 200 days after the first immunization. The cytokine profile was obtained by in vitro boosting with individual peptides in the absence of in vitro selection or CD4 enrichment.

Differences in cytokine and isotype profiles for different immunogens have been reported to be influenced by the selection of adjuvants (69). While a deeper analysis is beyond the scope of this report, the fact that all of the mice in this study received the LPCs emulsified in the same adjuvant suggests a real participation of the peptide constructs in the modulation of the specific cytokine and isotype profiles observed here. FA was chosen for the present study in order to be able to compare the humoral immune response with that obtained for the (NANP)3 epitope in numerous previous studies. Importantly, even more dramatic results were generated more recently in BALB/c mice with one of the LPCs by using clinical-grade adjuvants and subcutaneous immunization procedures (unpublished data).

Ongoing research must now investigate (i) the immune response to these and other LPCs in different strains of mice, (ii) the molecular mechanisms involved in the preferential induction of a particular Th1 or Th2 immunogenic profile, (iii) the potential synergic effect obtained by the combination of several promiscuous T-cell epitopes, (iv) the potential of including the reported Th epitopes with nonmalarial antigens, and (v) the magnitude and functional significance of LPC-specific memory cells. Several factors may influence the commitment of the immune response to Th1 or Th2 phenotypes in vivo (60). In particular, altered peptide ligands can lead to changes in the interaction between a T-cell receptor and an MHC-peptide complex. Altered peptide ligands have been shown to modify the kinetics of the immune response to well-defined T-cell epitopes (14). Recently, Ise and colleagues demonstrated a preferential Th1 or Th2 cytokine secretion profile in vitro using peptide analogues (35). In general, it has been suggested that increasing the affinity of the wild-type peptides for MHC class II alleles above baseline affinity leads to enhanced priming for Th1. In contrast, decreasing the affinity leads to the Th2 phenotype. It may be relevant in this regard that the PvT19-PfB3 chimera, which induced the highest antibody response, also had the highest affinity to two human alleles (50% inhibitory concentrations for DRB1∗0401 and DRB1∗1101, 11.45 and 19.14 μM), in contrast to 50% inhibitory concentrations ranging between 23 and 250 μM for the other LPCs (data not shown).

In summary, we have demonstrated the presence of eight promiscuous T-cell epitopes in the PvMSP-1 molecule. Novel synthetic LPC Cys-T-B-Cys constructs including these epitopes proved to be highly immunogenic in BALB/c mice. Functional (NANP)3 antibodies measured by ISI assays and cytokine profiles consistent with long-lasting Th activity were obtained after immunization in all animals tested, suggesting that the genetic restriction to B-cell epitopes is not an insurmountable obstacle to developing effective malaria vaccines. The remarkable immunogenicity of the linear peptides also suggests that complex synthetic structures or adjuvant-built peptides are not required to induce a vigorous immune response. The LPC approach described here expands the possibilities for rapidly producing and testing novel multimeric vaccines. Finally, we have shown that epitopes derived from different malaria parasite species and life cycle stages can be combined in a single linear peptide to form a very effective immunogen.


This research was supported by U.S. National Institutes of Health grant R01 AI24710-15 and Yerkes Regional Primate Research Center Base Grant 5 P51 RR00165-40 and by the Colombian Ministry of Health. J. Mauricio Calvo-Calle was the recipient of a visiting scientist award from Convenio Andres Bello-CECAB (Colciencias), which enabled his participation in this project at the Fundación Instituto de Inmunología de Colombia.

I.C.-A. and A.R. contributed equally to this work.

We thank Soraya Angel, Juan Carlos Gómez, and the personnel at the Battalion 21 Vargas, Granada, Meta, Colombia, for their assistance in obtaining blood samples. We are also grateful to the volunteers who willingly participated in these studies. We thank Elizabeth Nardin for kindly providing the Plasmodium CS protein anti-repeat MAbs, Joseli de Oliveira-Ferreira for her advice with ELISPOT assays and critical reading of the manuscript, John W. Barnwell for providing P. falciparum sporozoites and P. vivax schizonts for IFA analyses and critical review of the manuscript, and Vladimir Corredor for critical review of the manuscript.


Editor: S. H. E. Kaufmann


1. Arias, A. E., and A. Corredor. 1989. Low response of Colombian strains of Plasmodium vivax to classical antimalarial therapy. Trop. Med. Parasitol. 40:21-23. [PubMed]
2. Boykins, R. A., M. Joshi, C. Syin, S. Dhawan, and H. Nakhasi. 2000. Synthesis and construction of a novel multiple peptide conjugate system: strategy for a subunit vaccine design. Peptides 21:9-17. [PubMed]
3. Breman, J. G. 2001. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am. J. Trop. Med. Hyg. 64:1-11. [PubMed]
4. Brown, J. H., T. S. Jardetzky, J. C. Gorga, L. J. Stern, R. G. Urban, J. L. Strominger, and D. C. Wiley. 1993. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 364:33-39. [PubMed]
5. Calvo-Calle, J. M., J. Hammer, F. Sinigaglia, P. Clavijo, Z. R. Moya-Castro, and E. H. Nardin. 1997. Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein. J. Immunol. 159:1362-1373. [PubMed]
6. Cheng, Q., A. Stowers, T. Y. Huang, D. Bustos, Y. M. Huang, C. Rzepczyk, and A. Saul. 1993. Polymorphism in Plasmodium vivax MSA1 gene—the result of intragenic recombinations? Parasitology 106:335-345. [PubMed]
7. Conway, D. J., D. R. Cavanagh, K. Tanabe, C. Roper, Z. S. Mikes, N. Sakihama, K. A. Bojang, A. M. Oduola, P. G. Kremsner, D. E. Arnot, B. M. Greenwood, and J. S. McBride. 2000. A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses. Nat. Med. 6:689-692. [PubMed]
8. Del Giudice, G., J. A. Cooper, J. Merino, A. S. Verdini, A. Pessi, A. R. Togna, H. D. Engers, G. Corradin, and P. H. Lambert. 1986. The antibody response in mice to carrier-free synthetic polymers of Plasmodium falciparum circumsporozoite repetitive epitope is I-Ab-restricted: possible implications for malaria vaccines. J. Immunol. 137:2952-2955. [PubMed]
9. del Portillo, H. A., S. Longacre, E. Khouri, and P. H. David. 1991. Primary structure of the merozoite surface antigen 1 of Plasmodium vivax reveals sequences conserved between different Plasmodium species. Proc. Natl. Acad. Sci. USA 88:4030-4034. [PMC free article] [PubMed]
10. de Oliveira, C. I., G. Wunderlich, G. Levitus, I. S. Soares, M. M. Rodrigues, M. Tsuji, and H. A. del Portillo. 1999. Antigenic properties of the merozoite surface protein 1 gene of Plasmodium vivax. Vaccine 17:2959-2968. [PubMed]
11. Diethelm-Okita, B. M., D. K. Okita, L. Banaszak, and B. M. Conti-Fine. 2000. Universal epitopes for human CD4+ cells on tetanus and diphtheria toxins. J. Infect. Dis. 181:1001-1009. [PubMed]
12. Doolan, D. L., S. Southwood, R. Chesnut, E. Appella, E. Gomez, A. Richards, Y. I. Higashimoto, A. Maewal, J. Sidney, R. A. Gramzinski, C. Mason, D. Koech, S. L. Hoffman, and A. Sette. 2000. HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles. J. Immunol. 165:1123-1137. [PubMed]
13. Escalante, A. A., and F. J. Ayala. 1994. Phylogeny of the malarial genus Plasmodium, derived from rRNA gene sequences. Proc. Natl. Acad. Sci. USA 91:11373-11377. [PMC free article] [PubMed]
14. Faber-Elmann, A., V. Grabovsky, M. Dayan, M. Sela, R. Alon, and E. Mozes. 2001. An altered peptide ligand inhibits the activities of matrix metalloproteinase-9 and phospholipase C, and inhibits T cell interactions with VCAM-1 induced in vivo by a myasthenogenic T cell epitope. FASEB J. 15:187-194. [PubMed]
15. Falk, K., O. Rotzschke, S. Stevanovic, G. Jung, and H. G. Rammensee. 1991. Allele-specific motifs revealed by sequencing of self peptides eluted from MHC molecules. Nature 351:290-296. [PubMed]
16. Fernandez, I. M., A. Snijders, B. J. Benaissa-Trouw, M. Harmsen, H. Snippe, and C. A. Kraaijeveld. 1993. Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus. J. Virol. 67:5843-5848. [PMC free article] [PubMed]
17. Fernandez, I. M., H. Golding, B. J. Benaissa-Trouw, N. M. de Vos, M. Harmsen, H. S. Nottet, B. Golding, W. C. Puijk, R. H. Meloen, H. Snippe, and C. A. Kraaijeveld. 1998. Induction of HIV-1 IIIb neutralizing antibodies in BALB/c mice by a chimaeric peptide consisting of a T-helper cell epitope of Semliki Forest virus and a B-cell epitope of HIV. Vaccine 16:1936-1940. [PubMed]
18. Fernandez, I. M., M. Harmsen, B. J. Benaissa-Trouw, I. Stuij, W. Puyk, R. H. Meloen, H. Snippe, and C. A. Kraaijeveld. 1998. Epitope polarity and adjuvants influence the fine specificity of the humoral response against Semliki Forest virus specific peptide vaccines. Vaccine 16:1531-1536. [PubMed]
19. Fu, J., M. Hato, K. Igarashi, T. Suzuki, H. Matsuoka, A. Ishii, J. L. Leafasia, Y. Chinzei, and N. Ohta. 2000. A simple screening method for detecting bindings between oligopeptides and HLA-DR molecules on filter papers: possible application for mapping of putative helper T-cell epitopes on MSP1 of Plasmodium falciparum. Microbiol. Immunol. 44:249-257. [PubMed]
20. Galinski, M. R., C. C. Medina, P. Ingravallo, and J. W. Barnwell. 1992. A reticulocyte-binding protein complex of Plasmodium vivax merozoites. Cell 69:1213-1226. [PubMed]
21. Garraud, O., A. Diouf, I. Holm, R. Perraut, and S. Longacre. 1999. Immune responses to Plasmodium falciparum-merozoite surface protein 1 (MSP1) antigen. II. Induction of parasite-specific immunoglobulin G in unsensitized human B cells after in vitro T-cell priming with MSP119. Immunology 97:497-505. [PMC free article] [PubMed]
22. Gibson, H. L., J. E. Tucker, D. C. Kaslow, A. U. Krettli, W. E. Collins, M. C. Kiefer, I. C. Bathurst, and P. J. Barr. 1992. Structure and expression of the gene for Pv200, a major blood-stage surface antigen of Plasmodium vivax. Mol. Biochem. Parasitol. 50:325-333. [PubMed]
23. Good, M. F. 1995. Development of immunity to malaria may not be an entirely active process. Parasite Immunol. 17:55-59. [PubMed]
24. Good, M. F., and D. L. Doolan. 1999. Immune effector mechanisms in malaria. Curr. Opin. Immunol. 11:412-419. [PubMed]
25. Griesmann, G. E., D. J. McCormick, and V. A. Lennon. 1991. An avidin-biotin-peroxidase assay to detect synthetic peptides bound to polystyrene plates. J. Immunol. Methods 138:25-29. [PubMed]
26. Gutierrez, A., J. Vicini, M. E. Patarroyo, L. A. Murillo, and M. A. Patarroyo. 2000. Plasmodium vivax: polymorphism in the merozoite surface protein 1 gene from wild Colombian isolates. Exp. Parasitol. 95:215-219. [PubMed]
27. Hammer, J., B. Takacs, and F. Sinigaglia. 1992. Identification of a motif for HLA-DR1 binding peptides using M13 phage display libraries. J. Exp. Med. 176:1007-1013. [PMC free article] [PubMed]
28. Hammer, J., P. Valsasnini, K. Tolba, D. Bolin, J. Higelin, B. Takacs, and F. Sinigaglia. 1993. Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell 74:197-203. [PubMed]
29. Hammer, J., E. Bono, F. Gallazzi, C. Belunis, Z. Nagy, and F. Sinigaglia. 1994. Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J. Exp. Med. 180:2353-2358. [PMC free article] [PubMed]
30. Hammer, J., F. Gallazzi, E. Bono, R. W. Karr, J. Guenot, P. Valsasnini, Z. A. Nagy, and F. Sinigaglia. 1995. Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J. Exp. Med. 181:1847-1855. [PMC free article] [PubMed]
31. Hammer, J., T. Sturniolo, and F. Sinigaglia. 1997. HLA class II peptide binding specificity and autoimmunity. Adv. Immunol. 66:67-100. [PubMed]
32. Heppner, D. G., J. F. Cummings, C. F. Ockenhouse, K. E. Kester, J. A. Lyon, and D. M. Gordon. 2001. New World monkey efficacy trials for malaria vaccine development: critical path or detour? Trends Parasitol. 17:419-425. [PubMed]
33. Holder, A. A., J. A. Guevara Patino, C. Uthaipibull, S. E. Syed, I. T. Ling, T. Scott-Finnigan, and M. J. Blackman. 1999. Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria. Parasitologia 41:409-414. [PubMed]
34. Houghten, R. A. 1985. General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proc. Natl. Acad. Sci. USA 82:5131-5135. [PMC free article] [PubMed]
35. Ise, W., M. Totsuka, R. Takato, S. Hachimura, T. Sato, A. Ametani, Y. Kumagai, S. Habu, and S. Kaminogawa. 2000. Primary response of naive CD4(+) T cells to amino acid-substituted analogs of an antigenic peptide can show distinct activation patterns: Th1- and Th2-type cytokine secretion, and helper activity for antibody production without apparent cytokine secretion. FEBS Lett. 465:28-33. [PubMed]
36. Jackson, D. C., C. J. Fitzmaurice, L. E. Brown, and W. Zeng. 1999. Preparation and properties of totally synthetic immunogens. Vaccine 18:355-361. [PubMed]
37. Jardetzky, T. S., J. H. Brown, J. C. Gorga, L. J. Stern, R. G. Urban, J. L. Strominger, and D. C. Wiley. 1996. Crystallographic analysis of endogenous peptides associated with HLA-DR1 suggests a common, polyproline II-like conformation for bound peptides. Proc. Natl. Acad. Sci. USA 93:734-738. [PMC free article] [PubMed]
38. Jensen, P. E. 1997. Peptide binding and antigen presentation by class II histocompatibility glycoproteins. Polymers 43:303-322. [PubMed]
39. Joshi, M. B., A. A. Gam, R. A. Boykins, S. Kumar, J. Sacci, S. L. Hoffman, H. Nakhasi, and R. T. Kenney. 2001. Immunogenicity of well-characterized synthetic Plasmodium falciparum multiple antigen peptide conjugates. Infect. Immun. 69:4884-4890. [PMC free article] [PubMed]
40. Keitel, W. A., K. E. Kester, R. L. Atmar, A. C. White, N. H. Bond, C. A. Holland, U. Krzych, D. R. Palmer, A. Egan, C. Diggs, W. R. Ballou, B. F. Hall, and D. Kaslow. 1999. Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. Vaccine 18:531-539. [PubMed]
41. Kobayashi, H., M. Wood, Y. Song, E. Appella, and E. Celis. 2000. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res. 60:5228-5236. [PubMed]
42. Le, T. P., L. W. Church, G. Corradin, R. L. Hunter, Y. Charoenvit, R. Wang, P. de la Vega, J. Sacci, W. R. Ballou, N. Kolodny, S. Kitov, G. M. Glenn, R. L. Richards, C. R. Alving, and S. L. Hoffman. 1998. Immunogenicity of Plasmodium falciparum circumsporozoite protein multiple antigen peptide vaccine formulated with different adjuvants. Vaccine 16:305-312. [PubMed]
43. Lopez, M. C., Y. Silva, M. C. Thomas, A. Garcia, M. J. Faus, P. Alonso, F. Martinez, G. Del Real, and C. Alonso. 1994. Characterization of SPf(66)n: a chimeric molecule used as a malaria vaccine. Vaccine 12:585-591. [PubMed]
44. Macdonald, R. A., C. S. Hosking, and C. L. Jones. 1988. The measurement of relative antibody affinity by ELISA using thiocyanate elution. J. Immunol. Methods 106:191-194. [PubMed]
45. Moreno, A., P. Clavijo, R. Edelman, J. Davis, M. Sztein, D. Herrington, and E. Nardin. 1991. Cytotoxic CD4+ T cells from a sporozoite-immunized volunteer recognize the Plasmodium falciparum CS protein. Int. Immunol. 3:997-1003. [PubMed]
46. Moreno, A., P. Clavijo, R. Edelman, J. Davis, M. Sztein, F. Sinigaglia, and E. Nardin. 1993. CD4+ T cell clones obtained from Plasmodium falciparum sporozoite-immunized volunteers recognize polymorphic sequences of the circumsporozoite protein. J. Immunol. 151:489-499. [PubMed]
47. Munesinghe, D. Y., P. Clavijo, M. C. Calle, R. S. Nussenzweig, and E. Nardin. 1991. Immunogenicity of multiple antigen peptides (MAP) containing T and B cell epitopes of the repeat region of the P. falciparum circumsporozoite protein. Eur. J. Immunol. 21:3015-3020. [PubMed]
48. Nardin, E. H., D. A. Herrington, J. Davis, M. Levine, D. Stuber, B. Takacs, P. Caspers, P. Barr, R. Altszuler, and P. Clavijo. 1989. Conserved repetitive epitope recognized by CD4+ clones from a malaria-immunized volunteer. Science 246:1603-1606. [PubMed]
49. Nardin, E. H., G. A. Oliveira, J. M. Calvo-Calle, Z. R. Castro, R. S. Nussenzweig, B. Schmeckpeper, B. F. Hall, C. Diggs, S. Bodison, and R. Edelman. 2000. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes. J. Infect. Dis. 182:1486-1496. [PubMed]
50. Nardin, E. H., J. M. Calvo-Calle, G. A. Oliveira, R. S. Nussenzweig, M. Schneider, J. M. Tiercy, L. Loutan, D. Hochstrasser, and K. Rose. 2001. A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types. J. Immunol. 166:481-489. [PubMed]
51. Newton, P., and N. White. 1999. Malaria: new developments in treatment and prevention. Annu. Rev. Med. 50:179-192. [PubMed]
52. Nussenzweig, R. S., J. P. Vanderberg, H. Most, and C. Orton. 1969. Specificity of protective immunity produced by x-irradiated Plasmodium berghei sporozoites. Nature 222:488-489. [PubMed]
53. Nussenzweig, R. S. 1982. Progress in malaria vaccine development: characterization of protective antigens. Scand. J. Infect. Dis. Suppl. 36:40-45. [PubMed]
54. Nussenzweig, R. S., and V. Nussenzweig. 1989. Antisporozoite vaccine for malaria: experimental basis and current status. Rev. Infect. Dis. 11(Suppl. 3):S579-S585. [PubMed]
55. O'Hern, P. A., Z. G. Liang, C. S. Bambra, and E. Goldberg. 1997. Colinear synthesis of an antigen-specific B-cell epitope with a ‘promiscuous’ tetanus toxin T-cell epitope: a synthetic peptide immunocontraceptive. Vaccine 15:1761-1766. [PubMed]
56. Parra, M., G. Hui, A. H. Johnson, J. A. Berzofsky, T. Roberts, I. A. Quakyi, and D. W. Taylor. 2000. Characterization of conserved T- and B-cell epitopes in Plasmodium falciparum major merozoite surface protein 1. Infect. Immun. 68:2685-2691. [PMC free article] [PubMed]
57. Pessi, A., D. Valmori, P. Migliorini, C. Tougne, E. Bianchi, P. H. Lambert, G. Corradin, and G. Del Giudice. 1991. Lack of H-2 restriction of the Plasmodium falciparum (NANP) sequence as multiple antigen peptide. Eur. J. Immunol. 21:2273-2276. [PubMed]
58. Pimtanothai, N., M. Parra, A. H. Johnson, C. S. David, and C. Katovich Hurley. 2000. Assessing the binding of four Plasmodium falciparum T helper cell epitopes to HLA-DQ and induction of T-cell responses in HLA-DQ transgenic mice. Infect. Immun. 68:1366-1373. [PMC free article] [PubMed]
59. Rodriguez, R., A. Moreno, F. Guzman, M. Calvo, anad M. E. Patarroyo. 1990. Studies in owl monkeys leading to the development of a synthetic vaccine against the asexual blood stages of Plasmodium falciparum. Am. J. Trop. Med. Hyg. 43:339-354. [PubMed]
60. Rogers, P. R., and M. Croft. 1999. Peptide dose, affinity, and time of differentiation can contribute to the Th1/Th2 cytokine balance. J. Immunol. 163:1205-1213. [PubMed]
61. Sarin, V. K., S. B. Kent, J. P. Tam, and R. B. Merrifield. 1981. Quantitative monitoring of solid-phase peptide synthesis by the ninhydrin reaction. Anal. Biochem. 117:147-157. [PubMed]
62. Sinigaglia, F., M. Guttinger, J. Kilgus, D. M. Doran, H. Matile, H. Etlinger, A. Trzeciak, D. Gillessen, and J. R. Pink. 1988. A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature 336:778-780. [PubMed]
63. Soares, I. S., G. Levitus, J. M. Souza, H. A. Del Portillo, and M. M. Rodrigues. 1997. Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria. Infect. Immun. 65:1606-1614. [PMC free article] [PubMed]
64. Sood, A., P. Venugopalan, N. Mysore, and S. P. Vyas. 1998. Synthetic peptides: a modern approach to vaccination. Indian J. Exp. Biol. 36:849-861. [PubMed]
65. Southwood, S., J. Sidney, A. Kondo, M. F. del Guercio, E. Appella, S. Hoffman, R. T. Kubo, R. W. Chesnut, H. M. Grey, and A. Sette. 1998. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 160:3363-3373. [PubMed]
66. Stowers, A., and L. H. Miller. 2001. Are trials in New World monkeys on the critical path for blood-stage malaria vaccine development? Trends Parasitol. 17:415-419. [PubMed]
67. Su, Z., and M. M. Stevenson. 2000. Central role of endogenous gamma interferon in protective immunity against blood-stage Plasmodium chabaudi AS infection. Infect. Immun. 68:4399-4406. [PMC free article] [PubMed]
68. Tam, J. P., P. Clavijo, Y. A. Lu, V. Nussenzweig, R. Nussenzweig, and F. Zavala. 1990. Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria. J. Exp. Med. 171:299-306. [PMC free article] [PubMed]
69. ten Hagen, T. L., A. J. Sulzer, M. R. Kidd, A. A. Lal, and R. L. Hunter. 1993. Role of adjuvants in the modulation of antibody isotype, specificity, and induction of protection by whole blood-stage Plasmodium yoelii vaccines. J. Immunol. 151:7077-7085. [PubMed]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)
PubReader format: click here to try


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • MedGen
    Related information in MedGen
  • Nucleotide
    Primary database (GenBank) nucleotide records reported in the current articles as well as Reference Sequences (RefSeqs) that include the articles as references.
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...